Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea

  • End date
    Apr 9, 2024
  • participants needed
  • sponsor
    University of South Florida
Updated on 14 February 2022
obstructive sleep apnea
apnea-hypopnea index


The addition of intranasal oxymetazoline for two weeks to already instituted optimal doses of intranasal fluticasone propionate will decrease the total number of obstructive apneas and hypopneas per hour of sleep in subjects with perennial allergic or non-allergic rhinitis and mild obstructive sleep apnea who have persistent nasal congestion despite maximum doses of NGCS.


To evaluate the effectiveness of the addition of intranasal oxymetazoline to ongoing optimal doses of intranasal fluticasone propionate on the apnea/hypopnea index (AHI) in subjects with persistent nasal congestion and mild obstructive sleep apnea secondary to perennial allergic or non-allergic rhinitis despite treatment with the recommended doses of NGCS. The NOX T3 portable sleep monitor will be used to measure the AHI.

  1. The Flow Sensor, as part of the NOX T3 portable monitor, will be used to assess flow limitation of the upper airway through calculation of the flattening index, a marker of upper airway resistance.
  2. The Congestion Quantifier 7 (CQ7) questionnaire will be used to assess for an improvement in nasal congestion based on symptoms from the prior week.
  3. The Nasal Congestion Visual Analog Scale (VAS) will be used to identify the changes in the severity of nasal congestion on a day to day basis.
  4. The Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) will be used to assess the impact of perennial rhinitis and nasal congestion on activities of daily living.

Condition Sleep Apnea, Chronic Nasal Congestion
Treatment Placebo, Oxymetazoline Hydrochloride
Clinical Study IdentifierNCT02630121
SponsorUniversity of South Florida
Last Modified on14 February 2022


Yes No Not Sure

Inclusion Criteria

Male and female subjects 18 - 65 years of age
At least a one year history of perennial allergic or non-allergic rhinitis
Subjects must be on the maximum recommended doses of one of the following NGCS for at least one month. (See Table I)
AHI per hour of sleep > 5 and <15, minimum SpO2 88, indicating mild obstructive sleep apnea)
Average Nasal Congestion VAS of > 3-10 indicating moderate to severe nasal congestion between visits 1 and 2 based on daily symptoms (average of 7 scores)
Average Congestion Quantifier 7 score of 7 between visits 1 and 2 based on weekly symptoms (average of 2 scores)
Willingness to participate as indicated by signed informed consent

Exclusion Criteria

Presence of hypersensitivity to oxymetazoline or fluticasone propionate
Subjects receiving allergen immunotherapy but not on a stable maintenance regimen for at least 30 days before the first study visit
If the subject has perennial allergic rhinitis, he/she should not be entered into this study eight weeks before, during, or six weeks after any seasonal exacerbation
Women who are pregnant or lactating
Other known nasal diseases likely to affect deposition of oxymetazoline such as sinusitis, nasal polyps, or major nasal structural malformations
Respiratory tract infections in the last 14 days
Infections requiring antibiotics in the last 14 days
Asthma or chronic obstructive pulmonary disease (COPD) requiring roflumilast or more than the recommended doses of inhaled corticosteroids, beta agonists, or antimuscarinic agents
No systemic glucocorticosteroids for one month prior or during the study
Cardiovascular disease with uncontrolled hypertension (BP160/80), arrhythmias and/or congestive heart failure
Insulin-dependent diabetes mellitus and/or diabetic retinopathy
Subjects with mild OSA (AHI 5-14) and SpO2 <88 for > 5 min during sleep that is identified during the screening portable sleep study
Hypertension requiring more than two drugs, with the exception of hydrochlorothiazide, to achieve control
A history of drug or alcohol abuse within the past 5 years
Subjects who are currently abusing alcohol, illicit drugs, benzodiazepines, or narcotics
Inability to cooperate, comply with study procedures or communicate with the investigator to successfully complete the study
A history of benign prostate hypertrophy necessitating treatment
A history of psychiatric problems which, in the opinion of the investigators, would impair participation in the study
Subjects with a planned hospitalization during the study
An infirmity, disability, or geographical location which seems likely to prevent regular attendance for subject visits
Subjects with obstructive sleep apnea syndrome requiring CPAP therapy
Subjects diagnosed with central sleep apnea (> 5 central events per hour) or moderate to severe OSA (AHI > 15) and SpO2 <88 for > 5 min during sleep identified during screening
Use of the following medications within the time period specified below prior to Day -7 (Table 2)
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note